New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
09:09 EDTCERUCerulean announces CRLX101 combination data presented at ASCO
Cerulean Pharma announced that three abstracts on its lead candidate, CRLX101, were included in the 2014 American Society of Clinical Oncology Annual Meeting held in Chicago. An interim analysis of CRLX101 in combination with Avastin in a Phase 1b/2 clinical trial in patients with relapsed renal cell carcinoma, which was previously presented by Stephen Keefe, of the University of Pennsylvania Abramson Cancer Center at the ASCO Genitourinary Cancers Symposium in January, also was included in the ASCO Annual Meeting's electronic compendium of abstracts. This ongoing trial has shown that CRLX101 can be combined safely with Avastin, and preliminary outcomes suggest a clinical benefit in response rate and progression-free survival. The trial is being conducted at the Abramson Cancer Center and Thomas Jefferson University Hospital. The company said, "Collectively, these abstracts demonstrate the potential value of CRLX101 in combination with other cancer treatments across a range of cancers. We're working to advance CRLX101 in combination with other cancer treatments in all three indications, and we expect to launch a randomized trial in relapsed RCC this summer."
News For CERU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:05 EDTCERUCerulean announces research agreement with GOG for CRLX101
Cerulean Pharma announced it has signed a clinical research agreement with the GOG Foundation to conduct an open-label Phase 1b clinical trial of its lead product candidate, CRLX101, in combination with weekly paclitaxel in patients with relapsed ovarian cancer. Cerulean and the GOG Foundation have commenced start-up procedures and expect to enroll the first patient in Q2. This trial is being conducted by Cerulean in collaboration with the GOG Foundation under the direction of principal investigator Carolyn Krasner, M.D., of the Massachusetts General Hospital Cancer Center.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use